Abliva

Executive Summary

Abliva is a Swedish biopharmaceutical company dedicated to developing small molecule therapies for primary mitochondrial diseases, a group of rare, congenital, and severe disorders characterized by impaired cellular energy production. Founded in 2008 and headquartered in Lund, Abliva was acquired by Pharming Group N.V. in July 2025, becoming a wholly-owned subsidiary. The company's lead asset is KL1333, an oral substrate replacement therapy targeting mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) and other mitochondrial diseases. With a strong mechanistic rationale and early clinical data showing potential in reducing lactate levels and improving energy metabolism, KL1333 is poised to address a significant unmet medical need. The acquisition by Pharming provides Abliva with robust financial backing and commercial infrastructure, accelerating its development and regulatory pathways. Looking ahead, Abliva is advancing KL1333 through late-stage clinical development. The company expects to report top-line data from its pivotal Phase 2/3 trial in the first half of 2026, which could serve as a key regulatory submission package for marketing authorization in Europe and the US. Additionally, Abliva is exploring pipeline expansion into other mitochondrial indications, leveraging its mitochondrial biology expertise. With orphan drug and fast track designations from regulators, KL1333 has a clear path to market. The combination of a validated target, strategic parent company support, and imminent data readouts positions Abliva favorably for value creation.

Upcoming Catalysts (preview)

• H1 2026Top-line Phase 2/3 data readout for KL1333 in MELAS65% success
• H2 2026Regulatory submission (NDA/MAA) for KL133350% success
• 2026Initiation of Phase 2 trial for KL1333 in additional mitochondrial indication30% success